Management of undifferentiated thyroid cancer

2000 ◽  
Vol 14 (4) ◽  
pp. 615-629 ◽  
Author(s):  
Kenneth B Ain
Keyword(s):  
Thyroid Cancer ◽  
Undifferentiated Thyroid Cancer

Establishment and characterization of OCUT-1, an undifferentiated thyroid cancer cell line expressing high level of telomerase

2002 ◽  
Vol 80 (4) ◽  
pp. 197-203 ◽  
Author(s):  
Kana Ogisawa ◽  
Naoyoshi Onoda ◽  
Tetsuro Ishikawa ◽  
Chiemi Takenaka ◽  
Masaaki Inaba ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cell Line ◽  
Cancer Cell ◽  
Cancer Cell Line ◽  
Thyroid Cancer Cell ◽  
Thyroid Cancer Cell Line ◽  
High Level ◽  
Undifferentiated Thyroid Cancer

Chemotherapy of undifferentiated thyroid cancer (UCT) and sarcoma of the thyroid gland (ST)

1994 ◽  
pp. 295-297
Author(s):  
F. Kober ◽  
A. Heiss ◽  
B. Neugebauer ◽  
R. Roka
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Gland ◽  
Undifferentiated Thyroid Cancer

8-Cl-cAMP and PKA I-selective cAMP analogs effectively inhibit undifferentiated thyroid cancer cell growth

Endocrine ◽  
2016 ◽  
Vol 56 (2) ◽  
pp. 388-398
Author(s):  
Elisa Stellaria Grassi ◽  
Alessandra Dicitore ◽  
Irene Negri ◽  
Maria Orietta Borghi ◽  
Giovanni Vitale ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cell Growth ◽  
Cancer Cell ◽  
Thyroid Cancer Cell ◽  
Cancer Cell Growth ◽  
Undifferentiated Thyroid Cancer

Reversine, a 2,6-disubstituted Purine, as an Anti-cancer Agent in Differentiated and Undifferentiated Thyroid Cancer Cells

2012 ◽  
Vol 29 (7) ◽  
pp. 1990-2005 ◽  
Author(s):  
Shih-Che Hua ◽  
Tien-Chun Chang ◽  
Hau-Ren Chen ◽  
Chieh-Hsiang Lu ◽  
Yi-Wen Liu ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Cells ◽  
Anti Cancer ◽  
Cancer Agent ◽  
Undifferentiated Thyroid Cancer ◽  
Thyroid Cancer Cells

Optimization of Boron Neutron Capture Therapy for the Treatment of Undifferentiated Thyroid Cancer

2007 ◽  
Vol 69 (4) ◽  
pp. 1059-1066 ◽  
Author(s):  
Maria Alejandra Dagrosa ◽  
Lisa Thomasz ◽  
Juan Longhino ◽  
Marina Perona ◽  
Osvaldo Calzetta ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Boron Neutron Capture ◽  
Undifferentiated Thyroid Cancer

Evolution of tumor markers after external beam radiotherapy in the non-undifferentiated thyroid cancer

2018 ◽  
Author(s):  
Raquel Miralles Moragrega ◽  
Maria Maria Curras Freixes ◽  
Carolina Perdomo Zelaya ◽  
Javier Gargallo Vaamonde ◽  
Maria Llavero Valero ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Tumor Markers ◽  
External Beam Radiotherapy ◽  
External Beam ◽  
Undifferentiated Thyroid Cancer

scholarly journals Synergistic Signaling of KRAS and Thyroid Hormone Receptor β Mutants Promotes Undifferentiated Thyroid Cancer through MYC Up-Regulation

Neoplasia ◽  
2014 ◽  
Vol 16 (9) ◽  
pp. 757-769 ◽  
Author(s):  
Xuguang Zhu ◽  
Li Zhao ◽  
Jeong Won Park ◽  
Mark C. Willingham ◽  
Sheue-yann Cheng
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Hormone ◽  
Hormone Receptor ◽  
Thyroid Hormone Receptor ◽  
Thyroid Hormone Receptor Β ◽  
Undifferentiated Thyroid Cancer

scholarly journals The Effect of the Combined Action of Roscovitine and Paclitaxel on the Apoptotic and Cell Cycle Regulatory Mechanisms in Colon and Anaplastic Thyroid Cancer Cells

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
V. V. Pushkarev ◽  
O. I. Kovzun ◽  
V. M. Pushkarev ◽  
M. D. Tronko
Keyword(s):  
Thyroid Cancer ◽  
Cancer Cells ◽  
Anaplastic Thyroid Cancer ◽  
Cyclin Dependent Kinases ◽  
New Therapeutic Approaches ◽  
Drug Concentrations ◽  
Preclinical Trials ◽  
Combined Action ◽  
Undifferentiated Thyroid Cancer ◽  
Thyroid Cancer Cells

Aim. To study the significance of cyclin-dependent kinases (Cdks) in paclitaxel-dependent apoptosis in colon and undifferentiated thyroid cancer cells. Materials and Methods. Experiments were performed on undifferentiated thyroid carcinoma (KTC-2) and colon carcinoma (ARO) cell lines. Cells were treated with paclitaxel (Ptx) and inhibitor of Cdk, roscovitine. Cell survival test and Western blotting were used for characterization of the effects of paclitaxel and roscovitine on cancer cells. Results. It was shown that not c-Jun N-terminal kinase, but cyclin-dependent kinases are responsible for antiapoptotic Bcl-2 phosphorylation. Cdk inhibition enhanced the cytotoxic effects of Ptx at low drug concentrations. There was antagonism between Ptx and roscovitine at higher (25 nM) paclitaxel concentrations. Conclusion. Using of paclitaxel at low (2.5 to 5 nM) concentrations and roscovitine is a promising combination for further preclinical trials for the development of new therapeutic approaches to the treatment of colon and anaplastic thyroid cancer.

Sign in / Sign up

Export Citation Format

Share Document